Compare TD & JNJ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TD | JNJ |
|---|---|---|
| Founded | 1855 | 1886 |
| Country | Canada | United States |
| Employees | 70000 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 152.8B | 589.2B |
| IPO Year | N/A | 2003 |
| Metric | TD | JNJ |
|---|---|---|
| Price | $104.06 | $233.78 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 20 |
| Target Price | $120.00 | ★ $238.20 |
| AVG Volume (30 Days) | 2.6M | ★ 6.4M |
| Earning Date | 05-21-2026 | 04-14-2026 |
| Dividend Yield | ★ 2.96% | 2.18% |
| EPS Growth | N/A | ★ 90.50 |
| EPS | N/A | ★ 11.03 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $6.63 |
| Revenue Next Year | $4.48 | $7.24 |
| P/E Ratio | ★ $11.65 | $21.62 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $60.47 | $146.12 |
| 52 Week High | $104.08 | $251.71 |
| Indicator | TD | JNJ |
|---|---|---|
| Relative Strength Index (RSI) | 74.44 | 38.46 |
| Support Level | $92.13 | $201.37 |
| Resistance Level | N/A | $246.40 |
| Average True Range (ATR) | 1.40 | 4.56 |
| MACD | 1.08 | -0.69 |
| Stochastic Oscillator | 96.86 | 10.34 |
Toronto-Dominion is one of Canada's two largest banks with over CAD 2 trillion in assets. TD Bank operates four business segments: Canadian personal and commercial banking, US retail banking, wealth management and insurance, and wholesale banking. The bank derives more than 50% of its revenue from Canada and has dominant market share in nearly all banking products and services. TD has around 44% of its revenue from its US operations. Its US footprint spans from Maine to Florida, with a strong presence in the Northeast.
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.